Jfe Mineral Company, Ltd.

Koa Corporation

Koa Corporoation

Etsurou Udagawa

Yoshimi Nakata

Yuko Echizenya

Osamu Yamamoto

Kenichi Iguchi

Yoji Gomi

Chisaki Miura

Naomi Ishida

Focusing on zinc oxide itself, which is a main raw material for a zinc oxide varistor (laminated varistor), a predetermined amount of additive is added to a zinc oxide powder having crystallite size of 20 to 100 nm, particle diameter of 20 to 110 nm found using a specific area BET method, untamped density of 0.60 g/cmor greater, and tap density of 0.80 g/cmor greater. This allows a zinc oxide sintered body to secure uniformity, high density, and high electric conductivity, resulting in a zinc oxide varistor with high surge resistance, capable of downsizing and cost reduction. Moreover, addition of aluminum (Al), as a donor element, to the zinc oxide powder allows control of sintered grain size in conformity with the aluminum added amount and baking temperature, and also allows adjustment of varistor voltage, etc.

Zinc oxide varistor

Focus is on zinc oxide itself, which is a base material for a zinc oxide varistor (laminated varistor), wherein specified quantities of additives are added to a zinc oxide powder having a crystallite size of 20 to 50 nm, grain diameter of 15 to 60 nm found using the specific surface area BET method, untamped density of 0.38 to 0.50 g/cm, and tap density of 0.50 to 1.00 g/cm. This allows securing of uniformity, high compactness, and high electrical conductivity of a zinc oxide sintered body, and provision of a zinc oxide varistor having high surge resistance.

Zinc oxide varistor and method for manufacturing same

Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Therapeutic agent for skin wound or rough skin

An inorganic composition that is useful as an active ingredient for pharmaceuticals and has excellent stability comprises hydrozincite-containing zinc carbonate hydroxide hydrate produced by drying a precipitate. The precipitate is obtained by adding aqueous zinc nitrate solution, aqueous zinc sulfate solution or aqueous zinc chloride solution and aqueous sodium hydroxide solution dropwise to aqueous sodium hydrogen carbonate solution, a pH of the aqueous sodium hydrogen carbonate solution being maintained within a range of 6.5 to 9 by means of a pH controller. The hydrozincite-containing zinc carbonate hydroxide hydrate has an amount of dissolved Znions of not less than 0.1 &#x3bc;g/mbut not more than 7.33 &#x3bc;g/mand pH of not less than 7.2 and less than 8.3 after a dissolution test using stirring method.

Growing community of inventors

Tokyo, Japan

Etsurou Udagawa